The estimated Net Worth of Jennifer Schranz is at least $990 Thousand dollars as of 22 June 2018. Jennifer Schranz owns over 5,500 units of Nabriva Therapeutics Plc stock worth over $7,810 and over the last 7 years he sold NBRV stock worth over $0. In addition, he makes $982,155 as Chief Medical Officer at Nabriva Therapeutics Plc.
Jennifer has made over 1 trades of the Nabriva Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 5,500 units of NBRV stock worth $20,515 on 22 June 2018.
The largest trade he's ever made was buying 5,500 units of Nabriva Therapeutics Plc stock on 22 June 2018 worth over $20,515. On average, Jennifer trades about 306 units every 0 days since 2018. As of 22 June 2018 he still owns at least 5,500 units of Nabriva Therapeutics Plc stock.
You can see the complete history of Jennifer Schranz stock trades at the bottom of the page.
Dr. Jennifer Schranz M.D. serves as Chief Medical Officer of the Company. Previously, Dr. Schranz served as vice president, clinical research and development, global development team lead, for hereditary angioedema at Shire plc from January 2014 until March 2018. Prior to Shire, Dr. Schranz served as vice president of clinical development for ViroPharma, Inc. from March 2011 until January 2014. Before joining ViroPharma, Dr. Schranz was vice president, clinical research at Cempra, Inc., where she was responsible for clinical and regulatory strategy. Earlier in her career, Dr. Schranz worked in clinical development and medical affairs at several pharmaceutical companies, including Wyeth (now Pfizer), Vicuron Pharmaceuticals, Inc. (now Pfizer), GlaxoSmithKline plc, and Merck & Co. Inc. Dr. Schranz completed two years of biology and psychology at McMaster University prior to acceptance and subsequent completion of an M.D. from the University of Toronto, where she completed her internal medicine training and was a fellow in infectious diseases.
As the Chief Medical Officer of Nabriva Therapeutics Plc, the total compensation of Jennifer Schranz at Nabriva Therapeutics Plc is $982,155. There are 5 executives at Nabriva Therapeutics Plc getting paid more, with Colin Broom having the highest compensation of $2,044,990.
Jennifer Schranz is 55, he's been the Chief Medical Officer of Nabriva Therapeutics Plc since 2017. There are 11 older and 6 younger executives at Nabriva Therapeutics Plc. The oldest executive at Nabriva Therapeutics Plc is George Talbot, 72, who is the Independent member of the Supervisory Board.
Jennifer's mailing address filed with the SEC is 1000 Continental Dr #600, King of Prussia, PA 19406, USA.
Over the last 8 years, insiders at Nabriva Therapeutics Plc have traded over $3,221,169 worth of Nabriva Therapeutics Plc stock and bought 436,925 units worth $1,215,585 . The most active insiders traders include Capital Viii, Llc Vivo, Bioventures Cayman Ltd Hbm, and Charles A Jr Rowland. On average, Nabriva Therapeutics Plc executives and independent directors trade stock every 33 days with the average trade being worth of $23,562. The most recent stock trade was executed by Daniel D Burgess on 2 August 2022, trading 11,341 units of NBRV stock currently worth $2,155.
nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. nabriva was incorporated as a spin-off from sandoz gmbh antibiotics research institute (abri) in vienna, austria and commenced operations in february 2006. the new organization included small molecule assets, including pleuromutilin structure activity relationships (sar) knowledge and was focused on synthesis of pleuromutilins for systemic human use. following identification of our lead compound lefamulin and based on the clinical results of lefamulin for acute skin and skin structure infections. we believed that targeted in vitro spectrum of activity for the common pathogens causing community acquired bacterial pneumonia (cabp), wo
Nabriva Therapeutics Plc executives and other stock owners filed with the SEC include: